Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare technologies, is proud to announce that two of its portfolio companies, Pieris Pharmaceuticals ("Pieris") and Cellnovo Group SA ("Cellnovo") completed their respective Initial Public Offerings on Nasdaq and Euronext Paris.